But so far, the company is striking out in its attempts to broaden its label. On Thursday, BMS revealed that a phase 3 trial of Opdualag as an adjuvant treatment for patients with completely ...

In its results statement, the company said that the savings will be "driven by changes in organizational design and efforts to enhance operational efficiency" and would make BMS "a leaner ...

Orally-active mavacamten – which was acquired by BMS when it bought MyoKardia for $13 billion in 2020 – will launch under the Camzyos brand name with a list price of $89,500 per year.

The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts. Bristol Myers ...

After hours: March 12 at 7:51:23 PM EDT Loading Chart for BMY ...